Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human's middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window membrane, or a circulatory membrane. An otologic diagnostic device includes a nanoparticle conjugated with a material selected from the group consisting of lipids, proteins, growth factors, growth hormones, antioxidants, free radical scavengers, steroid preparations, and metabolically active substances; an otologic therapeutic device includes the same categories of substances and chemotherapeutic drugs. Another otologic composition includes a nanoparticle conjugated with a substance perceptible to magnetic resonance imaging.

A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.

An anti-vascular diseases and antitumor pharmaceutical composition is provided in the present invention, and it includes effective ingredients including bleomycin antitumor antibiotic, adrenal glucocorticoid, epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of (1-8):(2-5):(0.00005-0.001). The pharmaceutical composition provided can be used for treatment of vascular diseases and tumors.

The present invention relates to a nanoparticle comprising: an association of at least one metal salt and at least one peptide; and at least one biocompatible polymer.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

The present invention relates a method for preparing a personalized tumor vaccine using magnetic induction hyperthermia (MIH) inactivation technique, falling within the field of medicine. In this method, a MIH nanoagent is used to generate localized heat within tumor cells upon exposure to an alternating magnetic field, triggering immunogenic cell death and inducing the emergence of neoantigens mutations in tumor cells. Depending on the specific requirements, two strategies can be utilized: one involves preparing a whole tumor cell vaccine containing multiple tumor antigens, while the other focuses on screening specific tumor neoantigens to create a targeted tumor neoantigen vaccine. Mouse model experiments demonstrated that the whole tumor cell vaccine prepared using this method effectively inhibited the growth of homologous tumors, with a tumor-free rate of 100% in the vaccination group. Using MIH for tumor cells inactivation offers several advantages, including the preservation of antigen integrity, enhanced antigen abundance, and an increase in the diversity and quantity of released endogenous adjuvants. All of these factors contribute to the creation of a highly immunogenic personalized tumor vaccine, which holds promise for inhibiting tumor growth, recurrence and metastasis.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

A nanoparticle, which has a metal oxide core and a cerium shell is provided. The weight ratio of the cerium within the shell to the metal oxide in the core is at least 1%. Additionally a method for delivering a ligand into a cell with the nanoparticle is provided. Processes for making the nanoparticle which include: sonicating an aqueous composition containing Ceric Ammonium Nitrate and a prefabricated nano particle suspension; and (b) adding a polycationic polymer to the mixture (for NP surface functionalization), are also described.

A core-shell particle having an organic polymer core which is completely covered by a first inorganic oxide shell, wherein the first inorganic oxide shell has a silica (SiO2), an alumina (Al2O3), or a titania (TiO2); wherein the first inorganic oxide shell has a layer of a magnetic material which is disposed directly on the polymer core; further having a mesoporous second inorganic oxide shell, wherein the mesoporous second inorganic oxide shell covers the first inorganic oxide shell; wherein the mesoporous second inorganic oxide shell has silica (SiO2), alumina (Al2O3), or a titania (TiO2).